Cash position of €2.8 million, including €1 million of Research Tax Credit pre-financing implemented in early January 2024 Capital increase...
Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping the progression of...
Comme prévu initialement dans le protocole de l’étude, le Comité Indépendant de Surveillance des Données (IDMC – Independant Data Monitoring...
Over 200 patients randomized in this precision-medicine study, making it one of the largest randomized, double-blind, placebo-controlled trials...
Partnership to combine GeNeuro’s expertise in HERVs with Verily’s Immune Profiler and Workbench platforms to investigate biomarkers related to...
Strong financial position and visibility Cash position of €7.4 million Financing of activities assured into Q3 2024 Ongoing Phase II clinical...
Publication of data from novel mouse models mimicking expression of HERV-W in the central nervous system. Data confirms that the expression of...
Une publication récente montre qu’une infection par le SARS-CoV-2, même passée inaperçue ou asymptomatique, chez des patients psychotiques, peut...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads